Showing results (331-340 of 445) with videos related to
Sort By:
Pageof 45
Frontiers in Cardiovascular Medicine|July 23, 2026
Associations of parathyroid hormone and atrial fibrillation: epidemiological insights from the LURIC studyL König, M R Grübler, N Verheyen, et al.Allergy|November 15, 2013
Differences in the intrinsic immunogenicity and allergenicity of Bet v 1 and related food allergens revealed by site-directed mutagenesisA Roulias, U Pichler, M Hauser, et al.European Journal of Neurology|March 21, 2020
Monogenic cerebral small-vessel diseases: diagnosis and therapy. Consensus recommendations of the European Academy of NeurologyM Mancuso, M Arnold, A Bersano, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2012
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumorsJennifer A Chan, Keith Stuart, Craig C Earle, et al.Cancer|October 13, 2006
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumorsDavid P Ryan, Leonard J Appleman, Thomas Lynch, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2007
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancerMatthew H Kulke, Lawrence S Blaszkowsky, David P Ryan, et al.Journal of Palliative Medicine|April 8, 2017
Seeking and Accepting: U.S. Clergy Theological and Moral Perspectives Informing Decision Making at the End of LifeJustin J Sanders, Vinca Chow, Andrea C Enzinger, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancerBrian M Wolpin, Aram F Hezel, Thomas Abrams, et al.Neurology|November 9, 2005
Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trialsF Barkhof, U Held, J H Simon, et al.Journal of the Neurological Sciences|February 1, 2003
Low interleukin-10 production is associated with higher disability and MRI lesion load in secondary progressive multiple sclerosisH F Petereit, R Pukrop, F Fazekas, et al.Pageof 45